NK cell-activating fusion protein, NK cell, and pharmaceutical composition including same Grant US-11655306-B2 United States of America 23 May 2023
NK CELL-ACTIVATING FUSION PROTEIN, NK CELL, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME Application EP-3594242-A4 European Patent Office 09 Dec 2020
APPLICATION OF CHEMOKINE CXCL16 AND TUMOR NECROSIS FACTOR-α IN PREPARING DRUG FOR… Application WO-2018227734-A1 World Intellectual Property Organisation (WIPO) 20 Dec 2018